Abstract

ADJUVANT MIGRAINE MEDICATIONS IN THE TREATMENT OF SUDDEN SENSORINEURAL HEARING LOSS

*Dr. Yasien Abdritha Ajbara, Dr. Shaima Abd Muhsin AL Haboobi and Dr. Widad Musa Salman

ABSTRACT

Migraine is an extraordinarily common, chronic, intermittently disabling, and usually inherited neurovascular disorder. Patients with this condition typically suffer severe headache accompanied by autonomic symptoms, and a minority experience transient neurological symptoms known as an aura. The incidence of migraine peaks between 15 years and 24 years of age, 1 and the prevalence is highest among persons between the ages of 35 and 45 years. 2 In the United States, the one-year prevalence rate of migraine is estimated to be 17.6% in women and 5.7% in men, 2 and the cumulative lifetime incidence of migraine is 43% in women and 18% in men.1 Evidence suggests that migraine is underdiagnosed. One study reported that one-fourth of patients whose headaches met the criteria for migraine were not diagnosed as having this condition; 3 another found that approximately half of patients with migraine were undiagnosed. 4 Even when diagnosed, migraine is often undertreated. The frequency, duration, and intensity of migraine attacks can vary from person to person and from episode to episode. The majority of migraine patients experience periods of temporary disability that affect their work and leisure activities and, thus, their productivity and quality of life. This article reviews recent developments in the understanding and treatment of migraine.

Keywords: .